A 12-week, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CEP-10953 (150 mg) as treatment for adults with residual excessive sleepiness

Project: Research

StatusFinished
Effective start/end date1/01/0531/12/05